New combo offers hope for breast cancer that stopped responding to standard therapy
NCT ID NCT05305924
First seen Jan 28, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests a two-drug combination (fulvestrant and abemaciclib) in people with a common type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a standard treatment (a CDK4/6 inhibitor). The goal is to see if taking a break from the previous drug can make the cancer respond again to the new combination. About 28 participants will be enrolled, and the study will measure how long the treatment works before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.